RA
INDV icon

Royce & Associates’s Indivior Pharmaceuticals INDV Stock Holding History

Royce & Associates’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,900
Closed -$302K – 796
2026
Q1 		$302K Sell
9,900
-297,957
-97% -$9.84M ﹤0.01% 740
2025
Q4 		$11M Buy
307,857
+61,333
+25% +$1.87M 0.11% 280
2025
Q3 		$5.94M Buy
+246,524
New +$5.16M 0.06% 436

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's INDV Position: Q2 2026 in Review

Royce & Associates sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 9,900 shares — an estimated $302K sold.

Royce & Associates first reported a position in INDV in Q3 2025 and held it in 3 quarters. The position peaked at $11M in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Royce & Associates reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Royce & Associates sold 9,900 Indivior Pharmaceuticals shares in Q2 2026, an estimated $302K.
  • Royce & Associates first reported a position in Indivior Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Royce & Associates's Indivior Pharmaceuticals position peaked at $11M in Q4 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.